Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EBIT (2016 - 2025)

Historic EBIT for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $210.9 million.

  • Neurocrine Biosciences' EBIT rose 4852.11% to $210.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $619.1 million, marking a year-over-year increase of 851.88%. This contributed to the annual value of $619.1 million for FY2025, which is 851.88% up from last year.
  • As of Q4 2025, Neurocrine Biosciences' EBIT stood at $210.9 million, which was up 4852.11% from $239.0 million recorded in Q3 2025.
  • Neurocrine Biosciences' 5-year EBIT high stood at $239.0 million for Q3 2025, and its period low was -$114.2 million during Q1 2023.
  • Moreover, its 4-year median value for EBIT was $141.2 million (2023), whereas its average is $105.3 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' EBIT skyrocketed by 20045.15% in 2021, and later tumbled by 7623.36% in 2025.
  • Over the past 4 years, Neurocrine Biosciences' EBIT (Quarter) stood at $44.5 million in 2021, then soared by 237.75% to $150.3 million in 2023, then decreased by 5.52% to $142.0 million in 2024, then surged by 48.52% to $210.9 million in 2025.
  • Its last three reported values are $210.9 million in Q4 2025, $239.0 million for Q3 2025, and $145.6 million during Q2 2025.